Impact of COVID-19 on Business and Demand
First written in FY2020. 8 of 14 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2020: 102 of 175 companies on the "Worse" side.
- FY2026DroppedAnnual reportThe impact of COVID-19 on business and demand, which had been disclosed through the previous fiscal year, could not be identified as a separate item among the business or other risks in this annual securities report.
- FY2024-Q2RestatedAnnual report
「During the six-month period of the second quarter of the current consolidated fiscal year, Japan's economy showed signs of a gradual recovery as economic activity progressively returned to normal following the COVID-19 pandemic.」
The view that economic activity had been progressively returning to normal following the COVID-19 pandemic was expressed again, following the previous quarter. - FY2024-Q1MitigatedAnnual report
「Economic activity has been progressively returning to normal following the COVID-19 pandemic, and signs of a gradual recovery can be seen.」
The view was expressed that economic activity had been progressively returning to normal following the COVID-19 pandemic. Meanwhile, it was stated that there were no material changes to the business or other risks. - FY2023RestatedAnnual report
「If the spread of COVID-19 among Group employees expands, or if working from home and the closure of offices and factories at suppliers due to the spread of the infection continue for an extended period, this may affect the Group's operating results and financial condition.」
The risk disclosure that COVID-19 may affect business performance through employees, suppliers, research and development budgets and capital investment continues. - FY2023-Q3RestatedAnnual report
「During the nine-month period of the third quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
It was explicitly stated that there were no material changes to the business or other risks described in the previous fiscal year's report, including COVID-19. - FY2023-Q1RestatedAnnual report
「During the nine-month period of the first quarter of the current consolidated fiscal year, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
It was explicitly stated that there were no material changes from the previous fiscal year to the business or other risks, including the risk related to COVID-19. - FY2022-Q3WorsenedAnnual report
「During the nine-month period of the third quarter of the current consolidated fiscal year, Japan's economy remained uncertain, as the number of new COVID-19 cases temporarily declined but then increased again with the emergence of the Omicron variant, making the timing of containment difficult to foresee.」
The infection risk situation changed from a temporary decline in new cases to a renewed increase driven by the Omicron variant, and the view was expressed that the timing of containment could not be foreseen. - FY2022-Q2RestatedAnnual report
「The timing of the containment of COVID-19 remains uncertain, and if the impact of COVID-19 continues and expands worldwide, it may adversely affect the business performance and financial condition of the Group, including by worsening the operating conditions of the Company's and its customers' factories.」
The timing of the containment of COVID-19 remains uncertain, and the risk recognition that it may adversely affect factory operations, business performance and financial condition continues. - FY2022-Q1RestatedAnnual report
「The timing of the containment of COVID-19 remains uncertain, and if the impact of COVID-19 continues and expands worldwide, it may adversely affect the business performance and financial condition of the Group, including by worsening the operating conditions of the Company's and its customers' factories.」
The timing of the containment of COVID-19 remains uncertain, and the risk recognition that it may adversely affect factory operations, business performance and financial condition continues. - FY2021MaterialisedAnnual report
「Sales for the consolidated fiscal year amounted to ¥110,439 million, down 5.8% from the previous consolidated fiscal year. This was mainly attributable to the impact of COVID-19.」
COVID-19 was explicitly identified as a factor behind the full-year decline in sales, and its impact on demand for and sales of scientific and measuring instruments and medical equipment became evident in the results. - FY2021-Q3RestatedAnnual report
「The timing of the containment of COVID-19 remains uncertain, and if the impact of COVID-19 continues and expands worldwide, it may adversely affect the business performance and financial condition of the Group, including by worsening the operating conditions of the Company's and its customers' factories.」
The timing of the containment of COVID-19 remains uncertain, and the risk recognition that it may adversely affect business performance and financial condition continues. - FY2021-Q2RestatedAnnual report
「The timing of the containment of COVID-19 remains uncertain, and if the impact of COVID-19 continues and expands worldwide, it may adversely affect the business performance and financial condition of the Group, including by worsening the operating conditions of the Company's and its customers' factories.」
The timing of the containment of COVID-19 remains uncertain, and the risk recognition that it may adversely affect business performance and financial condition continues. - FY2021-Q1MaterialisedAnnual report
「The timing of the containment of COVID-19 remains uncertain, and if the impact of COVID-19 continues and expands worldwide, it may adversely affect the business performance and financial condition of the Group, including by worsening the operating conditions of the Company's and its customers' factories. Although overseas sales of automated biochemical analysers increased, overall sales remained at a low level due to the impact of COVID-19.」
The risk recognition that the timing of the containment of COVID-19 remains uncertain continued, and it was stated that sales in the medical equipment business remained at a low level due to the impact of the infection. - FY2020MaterialisedAnnual report
「If the spread of COVID-19 infections among the group's employees expands, if remote working or the closure of offices and factories at customer sites due to the spread of infections continues for an extended period, if government research and development budgets are reduced as a result of the spread of COVID-19, or if private-sector appetite for capital investment declines, the group's operating results, financial condition and other aspects of its business may be affected.」
COVID-19 was first disclosed as a separate risk affecting business performance and financial condition through employees, suppliers, government budgets and private-sector capital investment. It was also stated that performance was affected by the spread of the infection in the fourth quarter.